← 產業報告目錄
Peptide And Anticoagulant Drugs Market Size, Share & Trends Analysis Report by Peptide Drug Type (Antibiotic, Hormonal, Antifungal, ACE Inhibitor), Anticoagulant Drug Type (Heparin, Edoxaban, Apixaban, Dabigatran, Rivaroxaban), Administration Route (Oral, Injectable), By Peptide Application (Neurological Disorders, Metabolic Disorders, Gastrointestinal Disorders, Diabetes, Cancer, Cardiovascular Disorder, Infectious Diseases), Region And Segment Forecasts, 2025-2034
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-16頁數 180報告編號 INSIGHTACE-0f31adc20b
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Industry analysis indicates the Peptide And Anticoagulant Drugs Market globally will progress at a 5.0% CAGR during 2025–2034.
Peptide And Anticoagulant Drugs covers anticoagulants, which are chemical agents that decrease blood coagulation and the time it takes for blood to clot. Rapid advancements and evolving end-user preferences are reshaping how healthcare entities approach this space.
Growth is bolstered by a convergence of factors: rising awareness among end users, continuous product innovation, and the expanding emphasis on efficiency and sustainability within the healthcare sector.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, bolstered by rapid industrialization and expanding end-user bases.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Peptide and Anticoagulant Drugs Market Snapshot
Chapter 4. Global Peptide and Anticoagulant Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Peptide Drug Type Estimates & Trend Analysis
5.1. by Peptide Drug Type & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Peptide Drug Type:
5.2.1. Antibiotic
5.2.2. Hormonal
5.2.3. Antifungal
5.2.4. ACE Inhibitor
5.2.5. Others
Chapter 6. Market Segmentation 2: by Anticoagulant Drug Type Estimates & Trend Analysis
6.1. by Anticoagulant Drug Type & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Anticoagulant Drug Type:
6.2.1. Heparin
6.2.2. Edoxaban
6.2.3. Apixaban
6.2.4. Dabigatran
6.2.5. Rivaroxaban
6.2.6. Others
Chapter 7. Market Segmentation 3: by Administration Route Estimates & Trend Analysis
7.1. by Administration Route & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Administration Route:
7.2.1. Oral
7.2.2. Injectable
7.2.3. Others
Chapter 8. Market Segmentation 4: by Application Estimates & Trend Analysis
8.1. by Application & Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Application:
8.2.1. Neurological Disorders
8.2.2. Metabolic Disorders
8.2.3. Gastrointestinal Disorders
8.2.4. Diabetes
8.2.5. Cancer
8.2.6. Cardiovascular Disorder
8.2.7. Infectious Diseases
8.2.8. Others
Chapter 9. Peptide and Anticoagulant Drugs Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Peptide Drug Type, 2021-2034
9.1.2. North America Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Anticoagulant Drug Type, 2021-2034
9.1.3. North America Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Administration Route, 2021-2034
9.1.4. North America Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.1.5. North America Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.2. Europe
9.2.1. Europe Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Peptide Drug Type, 2021-2034
9.2.2. Europe Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Anticoagulant Drug Type, 2021-2034
9.2.3. Europe Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Administration Route, 2021-2034
9.2.4. Europe Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.2.5. Europe Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.3. Asia Pacific
9.3.1. Asia Pacific Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Peptide Drug Type, 2021-2034
9.3.2. Asia Pacific Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Anticoagulant Drug Type, 2021-2034
9.3.3. Asia-Pacific Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Administration Route, 2021-2034
9.3.4. Asia-Pacific Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.3.5. Asia Pacific Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.4. Latin America
9.4.1. Latin America Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Peptide Drug Type, 2021-2034
9.4.2. Latin America Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Anticoagulant Drug Type, 2021-2034
9.4.3. Latin America Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Administration Route, 2021-2034
9.4.4. Latin America Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.4.5. Latin America Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.5. Middle East & Africa
9.5.1. Middle East & Africa Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Peptide Drug Type, 2021-2034
9.5.2. Middle East & Africa Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Anticoagulant Drug Type, 2021-2034
9.5.3. Middle East & Africa Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Administration Route, 2021-2034
9.5.4. Middle East & Africa Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
9.5.5. Middle East & Africa Peptide and Anticoagulant Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Baxter
10.2.2. Celsus
10.2.3. Biofer
10.2.4. Hemmo Pharma
10.2.5. AmbioPharm
10.2.6. Wockhardt
10.2.7. Sun Pharmaceutical Industries
10.2.8. Bachem
10.2.9. Pfizer
10.2.10. Leo Pharma
10.2.11. Abbott Laboratories
10.2.12. Takeda
10.2.13. Aspen
10.2.14. Teva
10.2.15. Eli Lilly
10.2.16. Sanofi
10.2.17. Novo Nordisk
10.2.18. F. Hoffmann-La Roche Ltd.
10.2.19. Mylan N.V.
10.2.20. Teva Pharmaceutical Industries Ltd.
10.2.21. GlaxoSmithKline plc
10.2.22. Novartis AG
10.2.23. Merck & Co., Inc.
10.2.24. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們